Product Specific References | - Perez-Reyes, E., Van Deusen, A., Vitko, I. Molecular Pharmacology of Human Cav3.2 T-Type Ca2+ Channels: Block by Antihypertensives, Antiarrhythmics, and Their Analogs. JPET 328:621-7, 2009.
- Xie X, Van Deusen AL, Vitko I, Babu DA, Davies LA, Huynh N, Cheng H, Yang N,Barrett PQ, Perez-Reyes E. Validation of high throughput screening assays againstthree subtypes of Ca(v)3 T-type channels using molecular and pharmacologicapproaches. Assay Drug Dev Technol. 2007 Apr;5(2):191-203.
- Gomora JC, Murbartián J, Arias JM, Lee JH, Perez-Reyes E. Cloning andexpression of the human T-type channel Ca(v)3.3: insights into prepulsefacilitation. Biophys J. 2002 Jul;83(1):229-41.
- Shin SM, Lauzadis J, Itson-Zoske B, Cai Y, Fan F, Natarajan G, Kwok WM, Puopolo M, Hogan QH, Yu H. Targeting intrinsically disordered regions facilitates discovery of CaV3.2 inhibitory peptides for AAV-mediated peripheral analgesia. Pain. 2022 Apr 14. doi: 10.1097/j.pain.0000000000002650. Epub ahead of print. PMID: 35420557.
|